TriangleDISEASE & TREATMENT SETTING
EGFR-mutated advanced non-small cell lung cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Previously untreated locally advanced or metastatic non-small cell lung cancer with an activating EGFR exon 19 deletion or exon 21 L858R substitution.
- Source population
- Not part of this definition
- Disease extent
- metastatic
- Treatment line
- first-line
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- gene
- EGFR
- alteration
- exon 19 deletion
- status
- present
- gene
- EGFR
- alteration
- L858R
- status
- present
- prior therapy
- class
- any systemic therapy for advanced disease
- status
- none
- derivation status
- clinically-proposed
- derivation note
- Scoped from the FLAURA and FLAURA2 registered populations and the osimertinib first-line labelling. Not clinically reviewed.
- source wording
- Source null
Study evidence for this setting
Source relationships and population-mapping limitations
- bindings
- mappings
- release id
- clinical-indications-draft-1
- mapping id
- map-seer-lung
- disease state id
- ds-egfr-mutated-advanced-nsclc
- cohort id
- coh-seer-lung-and-bronchus
- mapping status
- broader
- mismatch explanation
- SEER's lung and bronchus grouping is not stratified by EGFR status and covers all histologies, stages and treatment lines. It cannot describe survival for this biomarker-defined, first-line population. No EGFR-specific SEER grouping is published.
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice